Trials / Completed
CompletedNCT03354884
caBozantinib in cOllectiNg ductS Renal Cell cArcInoma
caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, phase II trial (monocentric) study designed to determine To evaluate activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria in Metastatic Collecting Duct Renal Cell Carcinoma
Detailed description
This is a single-arm, phase II trial (monocentric)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cabozantinib | cabozantinib 60 mg orally once daily |
Timeline
- Start date
- 2018-01-12
- Primary completion
- 2020-11-19
- Completion
- 2020-11-19
- First posted
- 2017-11-28
- Last updated
- 2021-05-10
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03354884. Inclusion in this directory is not an endorsement.